Form 13-F position report

REATA PHARMACEUTICALS INC CL A

Reported by CPMG Inc

RETA CUSIP 75615P103 Manager CIK 0001372218

Reported 2,896,901 shares, unchanged from the prior quarter.

Reported value 51.2%; share count 0.0% vs. the prior quarter.

Unchanged
% of reported 13F value 27.63% This manager · Q4 2022
Shares 2,896,901 Quarter-end amount reported
Reported value $110,053,269 Fair value at quarter end
Consecutive quarters held 21 Through Q4 2022

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-06-30 409998000
2021-09-30 291457000
2021-12-31 76391000
2022-03-31 94902000
2022-06-30 88037000
2022-09-30 72799000
2022-12-31 110053269
2023-03-31 263386239
2023-06-30 295368026
2023-09-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

10 quarters
Quarterly reported position history for REATA PHARMACEUTICALS INC CL A held by CPMG Inc.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2023 Reduced 0 -2,896,901 (-100.0%) 0 $0 2023-11-14
Q2 2023 Unchanged 2,896,901 0 (0.0%) 59.26% $295,368,026 2023-08-14
Q1 2023 Unchanged 2,896,901 0 (0.0%) 53.13% $263,386,239 2023-05-15
Q4 2022 Unchanged 2,896,901 0 (0.0%) 27.63% $110,053,269 2023-02-14
Q3 2022 Unchanged 2,896,901 0 (0.0%) 14.28% $72,799,000 2022-11-14
Q2 2022 Unchanged 2,896,901 0 (0.0%) 17.69% $88,037,000 2022-08-15
Q1 2022 Unchanged 2,896,901 0 (0.0%) 15.92% $94,902,000 2022-05-16
Q4 2021 Unchanged 2,896,901 0 (0.0%) 14.09% $76,391,000 2022-02-14
Q3 2021 Unchanged 2,896,901 0 (0.0%) 32.14% $291,457,000 2021-11-15
Q2 2021 Unchanged 2,896,901 0 (0.0%) 67.78% $409,998,000 2021-08-16
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

194 managers reported REATA PHARMACEUTICALS INC CL A for Q4 2022.

Managers reporting REATA PHARMACEUTICALS INC CL A in Q4 2022.
Manager Activity Shares Change % of reported 13F Reported value Tenure
CPMG Inc This report Unchanged 2,896,901 0 27.63% $110,053,269 21 qtrs
VANGUARD GROUP INC Added 2,705,656 +52,356 < 0.01% $102,787,872 27 qtrs
BlackRock Inc Added 2,501,958 +6,587 < 0.01% $95,049,383 27 qtrs
First Light Asset Management LLC Added 2,062,453 +1,007,468 7.27% $78,352,589 2 qtrs
FRED ALGER MANAGEMENT LLC Added 1,509,404 +897,481 0.31% $57,342,258 2 qtrs
WELLINGTON MANAGEMENT GROUP LLP Reduced 1,507,882 -64,384 0.01% $57,284,437 15 qtrs
DEUTSCHE BANK AG Added 1,492,238 +472,726 0.03% $56,690,121 27 qtrs
ADAGE CAPITAL PARTNERS GP L L C Added 1,305,853 +1,065,829 0.12% $49,609,355 3 qtrs
Boxer Capital LLC Reduced 1,230,004 -8,996 2.46% $46,727,852 4 qtrs
Sofinnova Investments Inc Added 992,029 +173,653 2.24% $37,687,182 11 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
December 31, 2022
Filed
February 14, 2023
Filing type
13F-HR
Position type
CL A

Voting authority reported

Sole
2,896,901
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.